Helsinn Advanced Synthesis wins across all categories 2017 CMO Leadership Awards

Consistent strong performance sees Helsinn Advanced Synthesis SA win six awards for the third consecutive year in Quality, Reliability, Capabilities, Expertise and Compatibility, and the newest category – Development – earning a place among the best in the industry

Biasca, Switzerland, March 23, 2017 – Helsinn, the pharmaceutical Group focused on building quality cancer care products, today announces that its Swiss manufacturing company, Helsinn Advanced Synthesis SA, has for the third year running received awards at the CMO Leadership Awards, which recognize the leading contract manufacturing organizations based on real customer feedback conducted by Industry Standard Research. CMO Leadership award winners in the past have included Abbvie, Pfizer Centresource and GlaxoSmithKline among other high quality and highly regarded organizations.

This year Helsinn won six categories; Quality, Reliability, Capabilities, Expertise, Compatibility and Development for the ‘Overall’ group which combines both small and big pharma. Helsinn’s quality, expertise and commitment to its clients were recognized and highlighted at the presentation of the CMO Leadership Awards on 22 March 2017 at the W Hotel, Lexington Avenue, New York. As a recipient of the awards, Helsinn is also featured in the annual Life Science Leader’s award supplement which is an important resource for sponsors and CMOs alike.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “The criteria for CMO Leadership Awards mirror Helsinn Group’s own core values of quality, integrity and respect. It is a great honor and pleasing that Helsinn has been recognized for our continued commitment to improving our manufacturing process that in turn help to improve the everyday lives of cancer patients.”  

Waldo Mossi, Helsinn Advanced Synthesis’ General Manager, said: "We are delighted to have won across categories at this prestigious awards ceremony. The CMO Leadership Awards recognize the highest manufacturing quality globally and are respected amongst industry peers making this even more pleasing.”

"Industry Standard Research takes great pride in conducting the research for Life Science Leader’s CMO Awards, sourced from real experiences of industry peers over a period of 18 months.” Andrew Schafer, President of Industry Standard Research, commented. “We strive to provide valuable experiential feedback from real customers on their involvement with contract suppliers. Our stringent screening process and high caliber criteria mean that we collect feedback from only the most reliable and qualified sources to provide key insight for ISR research users”.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China as well as a product presence in about 90 countries globally.

Please visit www.helsinn.com.

About Helsinn Advanced Synthesis SA

Helsinn Advanced Synthesis SA is the manufacturing division of the Helsinn Group and develops and manufactures APIs, cGMP Advanced Intermediates, High Potency Active Ingredients (HPAPIs) and Anticancer compounds for third parties from clinical phase to commercial supply on an exclusive basis. The production plant is located in Biasca, Switzerland. The Biasca site is routinely inspected by the FDA and other global regulatory agencies.  Production scale ranges from grams for HPAPIs and Anticancer compounds and up to tens of tons for APIs in plants fully dedicated to cGMP manufacturing. 

 

Helsinn Group Contact:

Paola Bonvicini

Head of Communication & Press Office

+41 91-985-21-21

info-hhc@helsinn.com

 

Business Development Contact:

Helsinn Advanced Synthesis SA:

Sandra Moro

Director, Business Development

+41 91-873-94-30

sandra.moro@helsinn.com

http://www.helsinn.com/state-of-the-art-manufacturing